Expression of a deleted variant of human plasminogen in Escherichia coli

Растворение артериального тромба с помощью рекомбинантного белка — модифицированного плазмина человека — исследовали на живот- ной модели (бедренной артерии кролика). Опробованы различные способы моделирования артериального тромбоза, и как наиболее адекват- ный выбран способ поражения стенки сосуда путем механического повреждения артерии. При венозном тромбе введение рекомбинантного плазмина или рекомбинантной проурокиназы приводит к растворению тромба и восстанов- лению кровотока. При артериальном тромбе, полученном путем механического повреждения артерии, введение рекомбинантного плазмина или рекомбинантной проурокиназы не приводит к восстановлению кровотока в артерии кроликов из-за спазма сосуда. Введение папаверина в месте спазма устраняет спазм и восстанавливает кровоток. Это явление не описано в литературе, но служит препятствием при выборе адекватной модели артериального тромбоза Dissolution of arterial thrombus by recombinant human modified plasmin was examined in a rabbit model of femoral artery occlusion. Various ways to model arterial thrombosis have been tested. Mechanical damage to the artery was chosen as the most adequate method to model art erial thrombosis. Recombinant plasmin or prourokinase dissolve venous thrombus and restore blood flow. Due to vascular spasm these compounds fail to restore blood flow in arterial thrombosis caused by mechanical damage to the artery. Papaverin application at the site of spasm removes it and restores blood flow. This phenomenon is not described in the literature and hinders the choice of adequate model of arterial thrombosis

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Expression of a deleted variant of human plasminogen in Escherichia coli

Cited by 2 publications

References 16 publications

A Study of the Structure of Trypsin-Like Serine Proteinases. 2. A Study of Tryptophan Fluorescence in Variants of Miniplasminogen with an Altered Primary Structure

A Study of the Structure of Trypsin-Like Serine Proteinases. 2. A Study of Tryptophan Fluorescence in Variants of Miniplasminogen with an Altered Primary Structure

Choosing of suitable animal model of arterial thrombosis to test new recombinant thrombolytic agent — modified human plasminogen

Contact Info

Product

Resources

About